Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

How One Oncology Practice Took Advantage of Economies of Scale

November 12th 2013

One oncology practice in Florida seems to have been able to adapt its practice model, taking advantage of economies of scale, and identifying new revenue streams, while still providing quality care and keeping its oncologists satisfied professionally.

Drug Shortages Persist in Wake of Surveys

November 6th 2013

Headlines from the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago announced to the general public what oncologists and hematologists have known for more than two years: sporadic shortages of cancer drugs are forcing suboptimal treatment plans for patients, and government efforts have not filled the void.

FDA Approves Frontline Obinutuzumab for CLL

November 1st 2013

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Ponatinib Manufacturer Suspends Distribution

October 31st 2013

Marketing and commercial distribution of ponatinib has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of arterial thrombosis and severe narrowing of the blood vessels.

Mount Sinai Oncologists Improve Quality of Care for Cancer Patients with Standardized Criteria for Palliative Care Consultation

October 30th 2013

Intervention doubled palliative care consultations; lowered in-hospital mortality and hospital readmission rates.

Dr. Brahmer on Distinguishing Between Response and Growth

October 30th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses how physicians distinguish between a response to an immunotherapy and cancer growth.

The NYU Cancer Institute Joins OncLive's Strategic Alliance Partnership

October 29th 2013

Newest OncLive partner is a renowned translational cancer center that is at the forefront of comprehensive cancer treatment and research into advanced targeted therapies.

Dr. Thigpen on Ovarian Cancer Drugs Not Approved by FDA

October 29th 2013

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the use of agents in ovarian cancer that are not approved by the FDA.

Dr. Camidge Discusses Next-Generation Sequencing

October 24th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, explains excitement over the potential role for next-generation sequencing in cancer care.

FDA Grants Ramucirumab Priority Review for Advanced Gastric Cancer

October 23rd 2013

The FDA has assigned a priority review designation to ramucirumab as a second-line treatment for patients with advanced gastric cancer.

UCSF's Rugo to Chair OncLive's 'Giants of Cancer Care' Awards Program

October 21st 2013

Breast Oncology Director leads effort to honor luminaries who have helped patients survive

Evidence-Based Medicine: Examining the Gap Between Rhetoric and Reality

October 17th 2013

In many circumstances, the absence of so-called definitive evidence does not equate with the absence of evidence, just the level required by some to declare an approach to be an acceptable standard-of-care option.

Nanotech system, cellular heating may improve treatment of ovarian cancer

October 17th 2013

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs.

In a Surprise Finding, Gene Mutation Found Linked to Low-Risk Bladder Cancer

October 16th 2013

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability

October 15th 2013

Additional investment in and collaboration with ADC Therapeutics

Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization Management

October 14th 2013

Traditionally, payers have been increasingly more proactive in their management of drug expenditures in cancers with the highest prevalence and with the more costly therapeutics.

Researchers identify four genetic variants that are linked to esophageal cancer and its precursor, Barrett's esophagus

October 14th 2013

Findings from the first large-scale, genome-wide association study of esophageal adenocarcinoma may lead to new screening tools for those at high risk.

Leveraging Health Reform to Combat a History of Cancer

October 11th 2013

Governor Steve Beshear did not sugarcoat the data on May 9, 2013, when he said Kentucky would take an offer it couldn't refuse. With his state ranked worst in the nation in smoking and cancer deaths, and not far behind in heart disease, Beshear was "tired of being at the bottom."

Does Good Cholesterol Increase Breast Cancer Risk?

October 10th 2013

A protein receptor for the "good cholesterol," HDL, may help make breast cancer more aggressive and offer a new target for treating the disease.

When More Medicine Isn't Always Better: Penn Study Reveals High Costs of Unnecessary Radiation Treatments for Terminal Cancer Patients

October 9th 2013

More than 95 Percent of Advanced Prostate Cancer Patients Receive Multiple Radiation Treatments for Pain Control, Despite Evidence Pointing to Equal Benefit from Single Treatments